Cargando…
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over tim...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804680/ https://www.ncbi.nlm.nih.gov/pubmed/36054231 http://dx.doi.org/10.1002/ejhf.2652 |
_version_ | 1784862165240381440 |
---|---|
author | Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian L. de Boer, Rudolf A. Desai, Akshay S. Dobreanu, Dan Hernandez, Adrian F. Inzucchi, Silvio E. Jhund, Pardeep S. Kosiborod, Mikhail Lam, Carolyn S.P. Langkilde, Anna M. Lindholm, Daniel Martinez, Felipe A. O'Meara, Eileen Petersson, Magnus Shah, Sanjiv J. Thierer, Jorge McMurray, John J.V. Solomon, Scott D. |
author_facet | Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian L. de Boer, Rudolf A. Desai, Akshay S. Dobreanu, Dan Hernandez, Adrian F. Inzucchi, Silvio E. Jhund, Pardeep S. Kosiborod, Mikhail Lam, Carolyn S.P. Langkilde, Anna M. Lindholm, Daniel Martinez, Felipe A. O'Meara, Eileen Petersson, Magnus Shah, Sanjiv J. Thierer, Jorge McMurray, John J.V. Solomon, Scott D. |
author_sort | Ostrominski, John W. |
collection | PubMed |
description | AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. METHODS AND RESULTS: Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02–1.33]) and all‐cause death (adjusted HR 1.22 [1.06–1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70–0.94] for NYHA class II vs. HR 0.80 [0.65–0.98] for NYHA class III/IV; p (interaction) = 0.921). Participants with NYHA class III/IV had greater improvement in Kansas City Cardiomyopathy Questionnaire total symptom scores between baseline and 32 weeks (+4.8 [2.5–7.1]) versus NYHA class II (+1.8 [0.7–2.9]; p (interaction) = 0.011). Dapagliflozin was associated with higher odds of any improvement in NYHA class (odds ratio [OR] 1.32 [1.16–1.51]), as well as improvement to NYHA class I (OR 1.43 [1.17–1.75]), versus placebo at 32 weeks, with benefits seen as early as 4 weeks. CONCLUSIONS: Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time. |
format | Online Article Text |
id | pubmed-9804680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98046802023-01-06 Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian L. de Boer, Rudolf A. Desai, Akshay S. Dobreanu, Dan Hernandez, Adrian F. Inzucchi, Silvio E. Jhund, Pardeep S. Kosiborod, Mikhail Lam, Carolyn S.P. Langkilde, Anna M. Lindholm, Daniel Martinez, Felipe A. O'Meara, Eileen Petersson, Magnus Shah, Sanjiv J. Thierer, Jorge McMurray, John J.V. Solomon, Scott D. Eur J Heart Fail Focused Issue on Clinical Trials AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. METHODS AND RESULTS: Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02–1.33]) and all‐cause death (adjusted HR 1.22 [1.06–1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70–0.94] for NYHA class II vs. HR 0.80 [0.65–0.98] for NYHA class III/IV; p (interaction) = 0.921). Participants with NYHA class III/IV had greater improvement in Kansas City Cardiomyopathy Questionnaire total symptom scores between baseline and 32 weeks (+4.8 [2.5–7.1]) versus NYHA class II (+1.8 [0.7–2.9]; p (interaction) = 0.011). Dapagliflozin was associated with higher odds of any improvement in NYHA class (odds ratio [OR] 1.32 [1.16–1.51]), as well as improvement to NYHA class I (OR 1.43 [1.17–1.75]), versus placebo at 32 weeks, with benefits seen as early as 4 weeks. CONCLUSIONS: Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time. John Wiley & Sons, Ltd. 2022-08-27 2022-10 /pmc/articles/PMC9804680/ /pubmed/36054231 http://dx.doi.org/10.1002/ejhf.2652 Text en © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Focused Issue on Clinical Trials Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian L. de Boer, Rudolf A. Desai, Akshay S. Dobreanu, Dan Hernandez, Adrian F. Inzucchi, Silvio E. Jhund, Pardeep S. Kosiborod, Mikhail Lam, Carolyn S.P. Langkilde, Anna M. Lindholm, Daniel Martinez, Felipe A. O'Meara, Eileen Petersson, Magnus Shah, Sanjiv J. Thierer, Jorge McMurray, John J.V. Solomon, Scott D. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial |
title | Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial |
title_full | Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial |
title_fullStr | Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial |
title_full_unstemmed | Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial |
title_short | Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial |
title_sort | dapagliflozin and new york heart association functional class in heart failure with mildly reduced or preserved ejection fraction: the deliver trial |
topic | Focused Issue on Clinical Trials |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804680/ https://www.ncbi.nlm.nih.gov/pubmed/36054231 http://dx.doi.org/10.1002/ejhf.2652 |
work_keys_str_mv | AT ostrominskijohnw dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT vaduganathanmuthiah dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT claggettbrianl dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT deboerrudolfa dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT desaiakshays dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT dobreanudan dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT hernandezadrianf dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT inzucchisilvioe dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT jhundpardeeps dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT kosiborodmikhail dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT lamcarolynsp dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT langkildeannam dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT lindholmdaniel dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT martinezfelipea dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT omearaeileen dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT peterssonmagnus dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT shahsanjivj dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT thiererjorge dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT mcmurrayjohnjv dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial AT solomonscottd dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial |